Glenview Capital reduced its holdings in CVS Health Corp. (NYSE: CVS) by 3.75 million shares in May 2026, following what the investment firm described as healthy first-quarter results and increased annual guidance from the healthcare company.

The reduction was made to maintain diversification parameters and create buying power for other opportunities, according to a statement from the New York-based investment firm. CVS Health remains among Glenview's three largest positions, and the firm stated it has no plans for additional adjustments to its CVS holdings.

Glenview established its concentrated position in CVS Health shares in May 2024. The firm reported that CVS shares have generated an 80% total return since those initial purchases. The investment firm previously rebalanced its position in May 2025 and completed the resolution of a special purpose vehicle that was created in mid-2024 to invest exclusively in CVS Health shares.

The statement highlighted CVS Health's operational initiatives, including efforts to promote pharmacy reimbursement transparency, enhanced medication access and affordability, and improved prior authorization processes for medical claims. CVS Health employs approximately 300,000 associates.

Glenview Capital, operating for 26 years, describes itself as a long-term investment partnership focused on fundamental investing. The firm expressed continued confidence in CVS Health's near, medium, and long-term outlook.